Pulmonx Stock

Pulmonx Net Margin

The Net Profit Margin of Pulmonx (LUNG) as of Aug 12, 2026 is -59.67 %. In the previous year, Net Profit Margin was -67.30 % — a change of -11.34% (higher).

Net Margin

-59.67 %

YoY

-11.34%

Last updated:

Net Profit Margin of Pulmonx is 2026 -59.67 % . Net Profit Margin of Pulmonx was 2025 -67.30 % . It decreases by -11.34% higher compared to the previous year.

Pulmonx's net margin stands at -59.7%, up from -100.5% several years earlier.

Access this data via the Eulerpool API

Pulmonx Stock analysis

What does Pulmonx do? Pulmonx Corp is an innovative medical technology company based in the USA and Europe. The company specializes in the development of non-invasive solutions for the treatment of lung diseases. Pulmonx was founded in 1997 and has since introduced numerous groundbreaking technologies to the market that improve the quality of life for patients with chronic lung diseases. Pulmonx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Pulmonx stock

Net Profit Margin of Pulmonx is -59.67 % in 2026.

Net Profit Margin of Pulmonx changed from -67.30 % to -59.67 %, representing a -11.34% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Pulmonx since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Pulmonx with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Pulmonx

All Key Metrics — Pulmonx